{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:06:59Z","timestamp":1760267219773,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"FIGHT-MG project","award":["HEALTH-F2-2010-242210"],"award-info":[{"award-number":["HEALTH-F2-2010-242210"]}]},{"name":"CARIPLO Foundation","award":["2009.32550"],"award-info":[{"award-number":["2009.32550"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.jneuroim.2013.02.021","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T08:45:54Z","timestamp":1363855554000},"page":"41-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis"],"prefix":"10.1016","volume":"258","author":[{"given":"Roberta","family":"Marolda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Ruocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cordiglieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Toscani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Antozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvio","family":"Baggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2013.02.021_bb0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0019-2791(77)90291-9","article-title":"Immunochemical studies on acetylcholine receptor from Torpedo californica","volume":"14","author":"Aharonov","year":"1977","journal-title":"Immunochemistry"},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0010","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.4049\/jimmunol.172.4.2697","article-title":"Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats","volume":"172","author":"Baggi","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00005-011-0158-6","article-title":"Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?","volume":"60","author":"Baggi","year":"2012","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/WCO.0b013e328357a829","article-title":"Autoimmune mechanisms in myasthenia gravis","volume":"25","author":"Cavalcante","year":"2012","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jneuroim.2004.02.008","article-title":"Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis","volume":"151","author":"Cavaletti","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clim.1999.4807","article-title":"Animal models of myasthenia gravis","volume":"94","author":"Christadoss","year":"2000","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0035","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1212\/WNL.63.12_suppl_6.S28","article-title":"Mitoxantrone treatment of multiple sclerosis: safety considerations","volume":"63","author":"Cohen","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0040","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0045","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1474-4422(10)70007-7","article-title":"Combination therapy in multiple sclerosis","volume":"9","author":"Conway","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0050","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1093\/brain\/awq135","article-title":"Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system","volume":"133","author":"Cordiglieri","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0055","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0026-895X(25)10042-4","article-title":"Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives","volume":"48","author":"De Isabella","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1126\/science.182.4109.293","article-title":"Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors","volume":"182","author":"Fambrough","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0065","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1212\/WNL.59.6.909","article-title":"Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS","volume":"59","author":"Ghalie","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2012.06824.x","article-title":"Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?","volume":"1274","author":"Gomez","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0075","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1517\/14656566.8.8.1103","article-title":"Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis","volume":"8","author":"Gonsette","year":"2007","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0080","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0085","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1073\/pnas.74.7.3090","article-title":"Modulation of acetylcholine receptor by antibody against the receptor","volume":"74","author":"Heinemann","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0090","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.4049\/jimmunol.166.11.6893","article-title":"Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4","volume":"166","author":"Im","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jneuroim.2008.05.029","article-title":"Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil","volume":"201\u2013202","author":"Janssen","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0100","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1126\/science.850793","article-title":"Myasthenic immunoglobulin accelerates acetylcholine receptor degradation","volume":"196","author":"Kao","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0105","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.4049\/jimmunol.164.10.5236","article-title":"Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL\/6 mice","volume":"164","author":"Karachunski","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11910-010-0151-1","article-title":"Treatment of myasthenia gravis","volume":"11","author":"Kumar","year":"2011","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"Pt C","key":"10.1016\/j.jneuroim.2013.02.021_bb0115","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/0076-6879(81)74031-X","article-title":"Production and assay of antibodies to acetylcholine receptors","volume":"74","author":"Lindstrom","year":"1981","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/NDT.S8915","article-title":"Current and emerging therapies for the treatment of myasthenia gravis","volume":"7","author":"Mantegazza","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0125","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1212\/WNL.0b013e318238ee00","article-title":"Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone","volume":"77","author":"Martinelli","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jneuroim.2005.07.010","article-title":"Effects of Pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis","volume":"168","author":"Mazzanti","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0135","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.4049\/jimmunol.0903183","article-title":"Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis","volume":"185","author":"Nessi","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0140","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","article-title":"Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial","volume":"13","author":"Pettengell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0145","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0167-5699(97)80019-9","article-title":"The Th1\/Th2 paradigm","volume":"18","author":"Romagnani","year":"1997","journal-title":"Immunol. Today"},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0150","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3109\/08916930903518081","article-title":"Development of novel therapies for MG: studies in animal models","volume":"43","author":"Souroujon","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0155","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1002\/cncr.26121","article-title":"Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort","volume":"117","author":"Srokowski","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0160","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.4049\/jimmunol.180.4.2696","article-title":"Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats","volume":"180","author":"Ubiali","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2013.02.021_bb0165","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0167-5699(97)01151-1","article-title":"CD4+ T-cell subsets and cytokines involved in peripheral tolerance","volume":"18","author":"Weigle","year":"1997","journal-title":"Immunol. Today"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572813000593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572813000593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:20:03Z","timestamp":1759047603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572813000593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":33,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0165572813000593"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2013.02.021","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2013.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}